Clinical Chemistry · 1995 · 24 citations · 0 references
MedicineUrologyClinical EpidemiologyClinical ImmunologyPrecision MedicineBioanalytical Method ValidationBiomarker ValidationProstate CancerProstate-specific Antigen TestingLinear RegressionLot-to-lot VariabilityPercent Free Prostate-specific AntigenProstate-specific Antigen Assay StandardizationProstate-specific Antigen Test Performance
Abstract Equivalence between Hybritech Tandem and Abbott IMx PSA methods have been reported by some but not all previous investigators. To determine reasons for these differing conclusions, we measured serum PSA with three different lots each of IMx and Tandem-E kits. Overall, mean IMx results were significantly lower than Tandem-E results; however, for selected sera, the IMx results were consistently higher than the Tandem-E results. Lot-to-lot differences for the IMx method were significantly greater than those with the Tandem-E method. Most IMx/Tandem-E lot-to-lot comparisons had linear regression slopes that differed significantly from 1.0, but some did not. Conclusions concerning the equivalence of the IMx and the Tandem-E methods can be influenced both by variations in the proportions of free PSA in sera in tested populations and by lot-to-lot differences in the IMx method.